Jane A Gross

This inventor holds 52 USPTO granted patents and 21 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Cytokine Receptor Biology (CPC class C07K). Top assignees: Zymogenetics, Inc., University of Washington, Anergen, Inc.. Active years: 2000-2020.

USPTO Granted Patents = 52 (Patent Applications = 21)

% Patents Active = 34.6

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 15

Forward Citations = 844(Granted Patents)

Forward Citations (Not Self Cited) = 735(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

University of Washington

National Jewish Medical Research Center

patents

where one patent can have more than one assignee

Years Active: 2000-2020

Loading Chart...

Areas of Expertise:

Cytokine Receptors

TACI-Immunoglobulin Fusion Proteins

BCMA Protein Expression

ZCYTOR17 Ligand

IL-31 Antagonists

B Cell Cancers

Atopic Dermatitis

Glomerulonephritis

Therapeutic Response

Polynucleotides

Autoimmune Diseases

ZALPHA11 Ligand

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE48370 - Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus (2020-12-28),

2. 10227415 - Methods of producing a zcytor17 heterodimeric cytokine receptor (2019-03-12),

3. 9738700 - ZCYTOR17 heterodimeric cytokine receptor (2017-08-22),

4. 9725506 - Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus (2017-08-08),

5. 9605062 - Polynucleotides encoding ZCYTOR17 ligand antibodies (2017-03-28),

6. 9346878 - Methods of treating glomerulonephritis associated with IGA nephropathy for TACI-immunoglobulin fusion proteins (2016-05-24),

7. 9212213 - ZCYTOR17 heterodimeric cytokine receptor (2015-12-15),

8. 8926957 - Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells (2015-01-06),

9. 8815238 - Methods for Preparing TACI-immunoglobulin fusion proteins (2014-08-26),

10. 8784812 - Methods for treating autoimmune diseases using a TACI-Ig fusion molecule (2014-07-22),

11. 8778344 - Method of treating atopic dermatitis with antibody to zcytor17 ligand (2014-07-15),

12. 8647866 - ZCYTOR17 heterodimeric cytokine receptor polynucleotides (2014-02-11),

13. 8524232 - Methods of treatment using taci-immunoglobulin fusion proteins (2013-09-03),

14. 8435745 - Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells (2013-05-07),

15. 8388964 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells (2013-03-05),

Title: Innovator Spotlight: Jane A Gross - Pioneering Inventor from Seattle

Introduction: Jane A Gross, a trailblazing inventor hailing from Seattle, WA, is a formidable presence in the world of patents with an impressive portfolio of 52 patents to her name. Her cutting-edge inventions have significantly impacted the field of healthcare and autoimmune diseases.

Latest Patents: Among her recent patents is the groundbreaking innovation focusing on "Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus." This invention revolutionizes diagnostic assays by measuring BCMA levels on B cells, predicting autoimmune disease susceptibility, and tailoring treatment plans for individuals diagnosed with autoimmune diseases.

Career Highlights: Jane A Gross has made significant contributions during her tenure at renowned institutions such as Zymo Genetics, Inc. and the esteemed University of Washington. Her expertise and dedication to pushing the boundaries of medical science have yielded remarkable results, as evidenced by her extensive patent portfolio.

Collaborations: Throughout her illustrious career, Jane A Gross has collaborated with esteemed professionals in the field, including notable coworkers Cindy A Sprecher and Angela K Hammond. These collaborations have enriched her innovative endeavors and propelled her towards greater success in the realm of inventions and patents.

Conclusion: Jane A Gross stands as a true visionary in the realm of innovative healthcare solutions, with her pioneering work setting new standards for diagnostics and treatment of autoimmune diseases. Her relentless pursuit of excellence and collaboration with industry experts underscores her commitment to driving impactful change in the medical landscape.